{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T07:30:34Z","timestamp":1792654234548,"version":"4.5.0"},"reference-count":26,"publisher":"Impact Journals, LLC","issue":"51","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,7,12]]},"DOI":"10.18632\/oncotarget.19204","type":"journal-article","created":{"date-parts":[[2017,7,12]],"date-time":"2017-07-12T20:48:46Z","timestamp":1499892526000},"page":"89256-89268","source":"Crossref","is-referenced-by-count":182,"title":["A phase I trial of NK-92 cells for refractory hematological malignancies relapsing after autologous hematopoietic cell transplantation shows safety and evidence of efficacy"],"prefix":"10.18632","volume":"8","author":[{"given":"Brent A.","family":"Williams","sequence":"first","affiliation":[{"name":"Cell Therapy Program, Princess Margaret Cancer Centre, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arjun Datt","family":"Law","sequence":"additional","affiliation":[{"name":"Cell Therapy Program, Princess Margaret Cancer Centre, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Routy","sequence":"additional","affiliation":[{"name":"Cell Therapy Program, Princess Margaret Cancer Centre, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"denHollander","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, University Health Network, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[{"name":"Cell Therapy Program, Princess Margaret Cancer Centre, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xing-Hua","family":"Wang","sequence":"additional","affiliation":[{"name":"Cell Therapy Program, Princess Margaret Cancer Centre, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Am\u00e9lie","family":"Chaboureau","sequence":"additional","affiliation":[{"name":"Cell Therapy Program, Princess Margaret Cancer Centre, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sowmya","family":"Viswanathan","sequence":"additional","affiliation":[{"name":"Cell Therapy Program, Princess Margaret Cancer Centre, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armand","family":"Keating","sequence":"additional","affiliation":[{"name":"Cell Therapy Program, Princess Margaret Cancer Centre, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2017,7,12]]},"reference":[{"key":"1","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3109\/07357907.2014.919301","article-title":"Complications of allogeneic hematopoietic stem cell transplantation","volume":"32","author":"Tabbara","year":"2014","journal-title":"Cancer Invest"},{"key":"2","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Rosenberg","year":"2010","journal-title":"Mol Ther"},{"key":"3","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1038\/mt.2010.42","article-title":"Safer CARS","volume":"18","author":"Heslop","year":"2010","journal-title":"Mol Ther"},{"key":"4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/nbt0117-6b","article-title":"CAR-T\u2019s forge ahead, despite Juno deaths","volume":"35","author":"DeFrancesco","year":"2017","journal-title":"Nat Biotechnol"},{"key":"5","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1182\/asheducation-2016.1.567","article-title":"Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia","volume":"2016","author":"Porter","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"6","doi-asserted-by":"publisher","first-page":"e1115178","DOI":"10.1080\/2162402x.2015.1115178","article-title":"Advances in clinical NK cell studies: Donor selection, manufacturing and quality control","volume":"5","author":"Alici","year":"2016","journal-title":"Oncoimmunology"},{"key":"7","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1038\/ni.3518","article-title":"Targeting natural killer cells in cancer immunotherapy","volume":"17","author":"Smyth","year":"2016","journal-title":"Nat Immunol"},{"key":"8","doi-asserted-by":"publisher","first-page":"91","DOI":"10.3389\/fimmu.2016.00091","article-title":"Natural Killer Cells for Immunotherapy - Advantages of the NK-92 Cell Line over Blood NK Cells","volume":"7","author":"Toneguzzo","year":"2016","journal-title":"Front Immunol"},{"key":"9","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1080\/14653240802301872","article-title":"Infusion of the allogeneic cell line NK-92 in patients with advanced renal cell cancer or melanoma: a phase I trial","volume":"10","author":"Klingemann","year":"2008","journal-title":"Cytotherapy"},{"key":"10","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1016\/j.jcyt.2013.06.017","article-title":"Treatment of patients with advanced cancer with the natural killer cell line NK-92","volume":"15","author":"Bug","year":"2013","journal-title":"Cytotherapy"},{"key":"11","first-page":"652","article-title":"Characterization of a human cell line (NK-92) with phenotypical and functional characteristics of activated natural killer cells","volume":"8","author":"Klingemann","year":"1994","journal-title":"Leukemia"},{"key":"12","doi-asserted-by":"crossref","unstructured":"Boissel, Klingemann, Campbell, Nichols, Toneguzzo, Marcus, Williams, Keating, Soon-Shiong. An \u2018off the shelf,\u2019 GMP-grade, IL-2-independent NK cell line expressing the high-affinity Fc-receptor to augment antibody therapeutics (poster). IN: Annual Meeting of the American Association for Cancer Research. 2016.","DOI":"10.1158\/1538-7445.AM2016-2302"},{"key":"13","doi-asserted-by":"publisher","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor T cells for sustained remissions in leukemia","volume":"371","author":"Rheingold","year":"2014","journal-title":"N Engl J Med"},{"key":"14","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"June","year":"2011","journal-title":"N Engl J Med"},{"key":"15","doi-asserted-by":"publisher","first-page":"2980","DOI":"10.1182\/blood-2015-12-686725","article-title":"Phase 1 studies of central memory-derived CD19 CAR T-cell therapy following autologous HSCT in patients with B-cell NHL","volume":"127","author":"Budde","year":"2016","journal-title":"Blood"},{"key":"16","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1016\/j.ejso.2016.07.014","article-title":"Immunotherapy of melanoma","volume":"43","author":"McArthur","year":"2016","journal-title":"Eur J Surg Oncol"},{"key":"17","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa1411087","article-title":"PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin\u2019s Lymphoma","volume":"372","author":"Ligon","year":"2015","journal-title":"N Engl J Med"},{"key":"18","doi-asserted-by":"publisher","first-page":"15","DOI":"10.4137\/BIC.S29325","article-title":"Human Cancer Immunotherapy with PD-1\/PD-L1 Blockade","volume":"7","author":"Zhou","year":"2015","journal-title":"Biomarkers in Cancer"},{"key":"19","first-page":"14","article-title":"Monoclonal antibodies in cancer therapy","volume":"12","author":"Wolchok","year":"2012","journal-title":"Cancer Immun"},{"key":"20","doi-asserted-by":"publisher","first-page":"63","DOI":"10.3233\/hab-150286","article-title":"Licensed monoclonal antibodies and associated challenges","volume":"23","author":"Sadroddiny","year":"2015","journal-title":"Hum Antibodies"},{"key":"21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/14728214.2016.1257606","article-title":"Emerging biological therapies to treat acute lymphoblastic leukemia","author":"Tavitian","year":"2016","journal-title":"Expert Opin Emerg Drugs"},{"key":"22","doi-asserted-by":"publisher","first-page":"2097","DOI":"10.1126\/science.1068440","article-title":"Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants","volume":"295","author":"Velardi","year":"2002","journal-title":"Science"},{"key":"23","doi-asserted-by":"publisher","first-page":"3051","DOI":"10.1182\/blood-2004-07-2974","article-title":"Successful adoptive transfer andexpansion of human haploidentical NK cells in patients with cancer","volume":"105","author":"Wagner","year":"2005","journal-title":"Blood"},{"key":"24","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1200\/JCO.2009.24.4590","article-title":"NKAML: a pilot study to determine the safety and feasibility of haploidentical natural killer cell transplantation in childhood acute myeloid leukemia","volume":"28","author":"Leung","year":"2010","journal-title":"J Clin Oncol"},{"key":"25","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2011.054254","article-title":"Natural killer cell lines preferentially kill clonogenic multiple myelomacells and decrease myeloma engraftment in a bioluminescentxenograft mouse model","author":"Keating","year":"2012","journal-title":"Haematologica"},{"key":"26","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1148\/rg.335125214","article-title":"Response criteria in oncologic imaging: review of traditional and new criteria","volume":"33","author":"Sandrasegaran","year":"2013","journal-title":"Radiographics"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.19204","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,6]],"date-time":"2020-08-06T17:01:54Z","timestamp":1596733314000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.19204"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,12]]},"references-count":26,"journal-issue":{"issue":"51","published-print":{"date-parts":[[2017,10,24]]}},"alternative-id":["19204","29179517"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.19204","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,12]]}}}